JPH0838047A - Health food - Google Patents
Health foodInfo
- Publication number
- JPH0838047A JPH0838047A JP6192753A JP19275394A JPH0838047A JP H0838047 A JPH0838047 A JP H0838047A JP 6192753 A JP6192753 A JP 6192753A JP 19275394 A JP19275394 A JP 19275394A JP H0838047 A JPH0838047 A JP H0838047A
- Authority
- JP
- Japan
- Prior art keywords
- health food
- kefir
- cells
- interleukin
- natural killer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】この発明は、ケフイアの種々の薬
理作用を利用した健康食品を提供しようとするものであ
る。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is intended to provide health foods utilizing various pharmacological actions of kefir.
【0002】[0002]
【従来の技術】古来、ケフイアには種々の薬理作用があ
ると伝えられてきた。近年においては、マクロフア−ジ
の活性化(大石ら、第76回日本病理学会総会抄録号(198
7))、抗腫瘍作用(大石ら、Jpn. J. Dairy and Food Si
c., 37, 291(1988))、抗血栓作用(宮内ら、第80回日本
畜産学会要旨集(1987))、抗ストレス作用(谷ら、第47
回日本栄養・食料学会総会要旨集(1993))や免疫学的恒常
性作用(廣中ら、Jpn.J. Dairy and Food Sci., 40, 22
7(1991))など、免疫活性化に起因すると考えられる種々
の効果が明らかにされてきている。2. Description of the Related Art It has been reported from ancient times that kefir has various pharmacological actions. In recent years, activation of macrophages (Oishi et al., The 76th Annual Meeting of the Japanese Society of Pathology (198)
7)), antitumor effect (Oishi et al., Jpn. J. Dairy and Food Si
c., 37, 291 (1988)), antithrombotic action (Miyauchi et al., 80th Annual Meeting of the Japanese Society of Animal Science (1987)), antistress action (Tani et al., 47th).
Annual Meeting of the Japan Society of Nutrition and Food Science (1993)) and immunological homeostatic effects (Hiranaka et al., Jpn. J. Dairy and Food Sci., 40, 22).
7 (1991)), and various effects that are thought to be caused by immune activation have been clarified.
【0003】中でも大石ら(第76回日本病理学会総会抄
録号(1987))は、ケフイアの種々の薬理効果はマクロフ
ア−ジを活性することに起因することを当初から明らか
にしているが、その詳細については、不明の点が多く、
充分とは言えなかつた。Among them, Oishi et al. (The 76th Annual Meeting of the Japanese Society of Pathology (1987)) have made clear from the beginning that various pharmacological effects of kefir are due to activation of macrophages. For details, there are many unclear points,
It wasn't enough.
【0004】[0004]
【発明が解決しようとする課題】そこで発明者らはケフ
イア粒由来物質又はその培養液に、インタ−ロイキン1
の他にも、インタ−ロイキン12の産生を促す作用があ
ることを発見し、この発明に至つた。Therefore, the present inventors have added the interleukin-1 to the substance derived from kefir grains or the culture solution thereof.
In addition to the above, it was discovered that there is an action of promoting the production of interleukin 12, and the present invention was reached.
【0005】[0005]
【課題を解決するための手段】発酵乳や乳酸菌には、イ
ンタ−フエロンαやβの産生を増強させる作用がある(H
aruki Kitazawa,Kazuki Matsumura,Takatoshi Itoh and
Takahiro Yamaguchi;Interferon Induction in Murine
Peritoneal Macrophage by Stimulation withLactobac
illus acidophilus, Microbiol. Immunol., 36(3), 311
-315, 1992.Custy F.Fernandes and Khem M Shabami;An
ticarcinomgenic and ImmunologicalProperties of Die
tary Lactobacilli, J. Food Protection, 53(8), 704-
710,1990. 喜多 正和、岸田 綱太郎;ナリネ菌によるイ
ンタ−フエロン誘発とインタ−フエロン産生能増強作
用、基礎と臨床、21(12)、 71-74)ことが知られてい
る。しかし、これらはいずれもマクロフア−ジと乳酸菌
を一緒に培養しマクロフア−ジに異物認識させることに
より、それを活性化した結果生ずる現象であり、これら
乳酸菌を経口的に摂取する食品にした場合、その効果に
は問題点が多すぎる。[Means for Solving the Problems] Fermented milk and lactic acid bacteria have an action of enhancing the production of interferon α and β (H
aruki Kitazawa, Kazuki Matsumura, Takatoshi Itoh and
Takahiro Yamaguchi; Interferon Induction in Murine
Peritoneal Macrophage by Stimulation with Lactobac
illus acidophilus, Microbiol. Immunol., 36 (3), 311
-315, 1992.Custy F. Fernandes and Khem M Shabami; An
ticarcinomgenic and Immunological Properties of Die
tary Lactobacilli, J. Food Protection, 53 (8), 704-
710, 1990. Masakazu Kita, Tsunataro Kishida; Interferon induction and interferon productivity enhancement by N. cinerea, basic and clinical, 21 (12), 71-74). However, both of these are phenomena that result from activating them by culturing macrophages and lactic acid bacteria together and allowing the macrophages to recognize foreign substances, and when these lactic acid bacteria are taken as food to be taken orally, There are too many problems with its effect.
【0006】種々の癌患者やB型肝炎ウイルスキヤリ
ア、肝硬変患者などではα型及びγ型インタ−フエロン
の産生能が、それら疾患の進展と共に、低下しているこ
とが明らかにされているほか、健常者においても、加齢
と共にそれらの産生能が低下し、免疫能の低下による種
々の疾患に、宿主抵抗性の低下を招いていると考えられ
てきている。これらのインタ−フエロンのα型は白血球
型インタ−フエロンとも呼ばれ、非T細胞やナチユラル
キラ−細胞によつて産生される。In various cancer patients, hepatitis B virus carriers, patients with liver cirrhosis, etc., it has been revealed that the production ability of α-type and γ-type interferon decreases with the progress of these diseases. It has been considered that even in a healthy person, the ability to produce them decreases with aging, and various diseases caused by a reduction in immune ability lead to a reduction in host resistance. The α-type of these interferons is also called leukocyte-type interferon and is produced by non-T cells and natural killer cells.
【0007】また、γ型は主にT細胞やナチユラルキラ
−細胞によつて産生される。これらのインタ−フエロン
はそれぞれの細胞によつて、常時高濃度に産生されてい
るのではなく、種々の感染又は疾患を生じた場合、活発
になる。特にγ型インタ−フエロンの場合には、マクロ
フア−ジのインタ−ロイキン12の産生が必要である。The γ-type is mainly produced by T cells and natural killer cells. These interferons are not constantly produced in high concentrations by their respective cells, but become active when various infections or diseases occur. In particular, in the case of γ-type interferon, the production of macrophage interleukin 12 is required.
【0008】発酵乳や乳酸菌でマクロフア−ジを刺激し
た場合、インタ−ロイキン12の誘発が生じているのか
否かは不明である。しかし、ケフイアによる発酵物やケ
フイア粒によつては、経口投与、腹腔投与のいずれにお
いても、インタ−ロイキン12、インタ−フエロンα,
β,γの産生能や、ナチユラルキラ−細胞、ヘルパ−T
細胞が顕著に上昇していることから、従来知られている
乳酸菌や、それを使つた発酵乳による免疫系の活性化と
は、その作用機序が異なり、ケフイア粒及びケフイア粒
を使つた発酵物中に含まれる多くの微生物や、それらの
産生する多糖類、蛋白質糖の複合作用結果である。次に
実施例でより詳細にこの発明を説明する。When macrophages are stimulated with fermented milk or lactic acid bacteria, it is unclear whether or not interleukin 12 is induced. However, depending on the fermented product of kefir or the kefir grain, interleukin 12, interferon α,
β, γ production ability, natural killer cells, helper T
Since the cells are remarkably elevated, the mechanism of action is different from the activation of the immune system by conventionally known lactic acid bacteria and fermented milk using it, and the mechanism of action is different from that of kefir grains and fermentation using kefir grains. This is the result of the combined action of many microorganisms contained in the product, and the polysaccharides and protein sugars produced by them. Next, the present invention will be described in more detail with reference to Examples.
【0009】[0009]
【実施例】ケフイア粒(協同乳業(株)で保存している
ケフイア粒を、生理的食塩水によりよく洗浄した後、脱
イオン水で洗浄した物)又は発酵乳(協同乳業(株)で
保存しているケフイア粒を用い、これを牛乳に対し5%
(W/V)量添加した後、20゜Cで1週間静置発酵さ
せた物)を凍結乾燥し、10mg/mlになるように脱
イオン水に溶解し、80゜C、15分間加熱殺菌した。
この0.1ml〜0.5mlをC57/BLマウス(4
WKS,♂)に、胃ゾンデを用いて3日おきに2週間強
制経口投与した。マウスは5匹を1グル−プとして、同
一飼育ケ−ジ(アルミ製)で飼育し、飲料水は水道水を
自由摂取させた。また飼料は飼育繁殖固形飼料(日本ク
レア(株)製を用いた。なお対照として脱脂乳と凍結乾
燥した市販のヨ−グルトを同一濃度に溶解して用いた。[Examples] Kefir grains (Kefir grains stored in Kyodo Dairy Co., Ltd. were washed thoroughly with physiological saline and then washed with deionized water) or fermented milk (Kyodo Dairy Co., Ltd.) 5% of milk is used
After adding (W / V) amount, the mixture was left to stand and ferment at 20 ° C for 1 week, lyophilized, dissolved in deionized water to 10mg / ml, and sterilized by heating at 80 ° C for 15 minutes. did.
0.1 ml to 0.5 ml of this C57 / BL mouse (4
WKS, ♂) was forcibly orally administered every 3 days for 2 weeks using a gastric sonde. The mice were bred in the same breeding cage (made of aluminum) with 5 mice as one group, and tap water was freely ingested. The feed used was a breeding breeding solid feed (produced by CLEA Japan, Inc.) As a control, skim milk and freeze-dried commercially available yogurt were dissolved in the same concentration and used.
【0010】インタ−ロイキン12とインタ−フエロン
α,β及びγは血清を常法にて調整しBlAcore(フアル
マシア社製)を用いた共鳴プラズモン法による免疫検定
法でRU(Resonunce unit)を測定した。NK細胞とHelper
T細胞は末梢血中の各細胞のリンパ球に対する割合(%)
をフロ−サイドメ−タ−(FACScan, ベクトンデキンソン
社製)を用いて測定した。その結果を表1ないし表3に
示す。For interleukin 12 and interferons α, β and γ, RU (Resonunce unit) was measured by an immunoassay by resonance plasmon method using BlAcore (manufactured by Pharmacia) with serum prepared by a conventional method. . NK cells and Helper
T cell is the ratio of each cell in peripheral blood to lymphocytes (%)
Was measured using a flow side meter (FACScan, manufactured by Becton Dekinson). The results are shown in Tables 1 to 3.
【0011】[0011]
【表1】 [Table 1]
【0012】[0012]
【表2】 [Table 2]
【0013】[0013]
【表3】 [Table 3]
Claims (5)
いは両者を活性化し、インタ−ロイキン12の産生を促
すことを特徴とするケフイア粒、ケフイア培養液又はこ
れらの抽出部を含有する健康食品。1. A health food containing a kefir grain, a kefir culture solution, or an extract thereof, which activates either or both macrophages and B cells to promote the production of interleukin 12.
を生じさせることを特徴とする請求項1記載の健康食
品。2. The health food according to claim 1, which causes production of interferons α, β and γ.
胞に対して直接の細胞増殖作用を有することを特徴とす
る請求項1記載の健康食品。3. The health food according to claim 1, which has a direct cell proliferating effect on activated T cells and activated natural killer cells.
ことを特徴とする請求項1記載の健康食品。4. The health food according to claim 1, which enhances natural chiral cell activity.
導することを特徴とする請求項1記載の健康食品。5. The health food according to claim 1, which induces lymphokine-activated killer cell activity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6192753A JPH0838047A (en) | 1994-07-26 | 1994-07-26 | Health food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6192753A JPH0838047A (en) | 1994-07-26 | 1994-07-26 | Health food |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0838047A true JPH0838047A (en) | 1996-02-13 |
Family
ID=16296482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6192753A Pending JPH0838047A (en) | 1994-07-26 | 1994-07-26 | Health food |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0838047A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10139674A (en) * | 1996-11-11 | 1998-05-26 | Yakult Honsha Co Ltd | Production promoter of interleukin 12 |
JP2006076961A (en) * | 2004-09-10 | 2006-03-23 | Shikoku Nyugyo Kk | Immunopotentiator composition |
JP2007137864A (en) * | 2005-11-22 | 2007-06-07 | Yonezawa Biru System Service:Kk | Microorganism culture having effects for inhibiting onset of dermatitis and promoting recovery of skin wound, and product using the same |
JP2008081461A (en) * | 2006-09-28 | 2008-04-10 | Kyushu Univ | Drug using kefir, method for producing the same and healthy food |
-
1994
- 1994-07-26 JP JP6192753A patent/JPH0838047A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10139674A (en) * | 1996-11-11 | 1998-05-26 | Yakult Honsha Co Ltd | Production promoter of interleukin 12 |
JP2006076961A (en) * | 2004-09-10 | 2006-03-23 | Shikoku Nyugyo Kk | Immunopotentiator composition |
JP4688457B2 (en) * | 2004-09-10 | 2011-05-25 | 四国乳業株式会社 | Immune enhancing composition |
JP2007137864A (en) * | 2005-11-22 | 2007-06-07 | Yonezawa Biru System Service:Kk | Microorganism culture having effects for inhibiting onset of dermatitis and promoting recovery of skin wound, and product using the same |
JP2008081461A (en) * | 2006-09-28 | 2008-04-10 | Kyushu Univ | Drug using kefir, method for producing the same and healthy food |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yadav et al. | Composition, nutritional and therapeutic values of goat milk: A review | |
Arakawa et al. | Zinc deficiency in two infants during total parenteral alimentation for diarrhea | |
Walter et al. | Iron, anemia, and infection | |
EP3033091B1 (en) | Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma | |
Jelliffe et al. | Human milk, nutrition, and the world resource crisis | |
CA2266859C (en) | Colostrinin, and uses thereof | |
CN1070371C (en) | Method of treatment of HIV-seropositive individuals with dietary whey proteins | |
CN110892990B (en) | Probiotic and prebiotic edible composition and application thereof | |
FR2537436A1 (en) | METHOD FOR REGULATING APPETITE AND EFFICIENCY IN THE USE OF FOODS USING INTERFERON | |
JPH0838047A (en) | Health food | |
Lukasewycz et al. | Splenocytes from copper-deficient mice are low responders and weak stimulators in mixed lymphocyte reactions | |
Gillman | Effects on Rats of Prolonged Staple African Diet | |
JPH08500108A (en) | Anti-cancer therapeutic composition for preventing or treating cancer | |
Good et al. | Diet, immunity and longevity | |
JPS62166841A (en) | Ganglioside-containing powdered milk | |
Crane | Pro and anti: the biotics of allergic disease | |
JP4787445B2 (en) | Antigen-specific IgE antibody production inhibitor | |
Sober et al. | Nutrition of the guinea pig | |
CN1135933C (en) | Multifunctional nutritive liquid and its producing method | |
JP3150162B2 (en) | Oral opportunistic infection prevention / treatment composition | |
CN117530955B (en) | Preparation for preventing and treating mastitis and application thereof | |
TWI705817B (en) | Use of Lactobacillus embryo TWC10 for preparing anti-inflammatory pharmaceutical composition after exercise | |
Gonzalez Cabrera et al. | Goat kids are not affected by the intramammary administration of lipopolysaccharides at parturition | |
HORIKOSHI | Significant differences in natural killer cell activity in children according to age and sex | |
Spies et al. | DETECTION AND TREATMENT OF NUTRITIVE FAILURE IN CHILDREN: RECENT OBSERVATIONS |